Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GYRE THERAPEUTICS, INC.CBIO · Entity 5247 | Director | June 09, 2021 | July 02, 2021 |
| Structure Therapeutics Inc.GPCR · Entity 1222 | Director | June 17, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GYRE THERAPEUTICS, INC.
Report date June 09, 2021 · Filed July 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.55 · Expires 2031-06-09 | Direct | 14,000 |
Reported balance
After 2021-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-09 · Grant · Acquired 14,000 · Balance 14,000 F1: 100% of the shares subject to the option will vest and become exercisable on June 9, 2022, the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option will vest and become exercisable on June 9, 2022, the one-year anniversary of the grant date.
Structure Therapeutics Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2036-06-16 | Direct | 39,453 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 39,453 · Balance 39,453 F1: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2: The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting, F3: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").
F2: The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting,
F3: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
DICE Therapeutics, Inc.
Report date August 09, 2023 · Filed August 09, 2023
Section 16 reporting ended · disclosed 2023-08-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-08-09 transaction · row 1
1 source rowRow 1 · 2023-08-09 · Disposition to issuer · Disposed 49,841 · Balance 0 F1: On June 18, 2023, DICE Therapeutics, Inc., a Delaware corporation (the "Issuer" or the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Durning Acquisition Corporation, a Delaware corporation and a direct or indirect wholly owned subsidiary of the Parent (the "Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 9, 2023, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased for $48.00 per share (the "Offer Price"), without interest, less any applicable withholding taxes or (y) automatically converted into the right to receive an amount in cash without interest, equal to the Offer Price, less any applicable withholding taxes. Immediately prior to the Closing, any repurchase rights of the Company or other similar restrictions on the Common Stock fully lapsed and all Common Stock became fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2031-09-14 | Direct | 0 |
Reported balance
After 2023-08-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-09 · Disposition to issuer · Disposed 12,096 · Balance 0 F4: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company's Stock Option (the "Option") vests as to 1/36th of the total shares monthly, beginning November 8, 2020, subject to the Reporting Holder's continued service to the Registrant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2031-09-14 | Direct | 0 |
Reported balance
After 2023-08-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-08-09 · Disposition to issuer · Disposed 8,261 · Balance 0 F4: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F5: The Option vests as to 1/36th of the total shares monthly, beginning January 1, 2021, subject to the Reporting Holder's continued service to the Registrant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2031-09-14 | Direct | 0 |
Reported balance
After 2023-08-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-08-09 · Disposition to issuer · Disposed 13,800 · Balance 0 F4: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F6: The Option vests as to 1/48th of the total shares monthly, beginning August 20, 2021, subject to the Reporting Holder's continued service to the Registrant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.98 · Expires 2032-06-06 | Direct | 0 |
Reported balance
After 2023-08-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-08-09 · Disposition to issuer · Disposed 21,250 · Balance 0 F4: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F7: The Option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 18, 2023, DICE Therapeutics, Inc., a Delaware corporation (the "Issuer" or the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Durning Acquisition Corporation, a Delaware corporation and a direct or indirect wholly owned subsidiary of the Parent (the "Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.
F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 9, 2023, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased for $48.00 per share (the "Offer Price"), without interest, less any applicable withholding taxes or (y) automatically converted into the right to receive an amount in cash without interest, equal to the Offer Price, less any applicable withholding taxes. Immediately prior to the Closing, any repurchase rights of the Company or other similar restrictions on the Common Stock fully lapsed and all Common Stock became fully vested.
F3: The Company's Stock Option (the "Option") vests as to 1/36th of the total shares monthly, beginning November 8, 2020, subject to the Reporting Holder's continued service to the Registrant.
F4: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof.
F5: The Option vests as to 1/36th of the total shares monthly, beginning January 1, 2021, subject to the Reporting Holder's continued service to the Registrant.
F6: The Option vests as to 1/48th of the total shares monthly, beginning August 20, 2021, subject to the Reporting Holder's continued service to the Registrant.
F7: The Option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 18, 2026 21:00 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | GrantShare Option (right to buy) · Derivative | 39,453 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001328565-26-000002 · form4-06182026_050604.xml · derivative · entry 1 TETLOW SHARON · CIK 0001328565 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,453 Underlying: Ordinary Shares · 39,453 shares Expires 2036-06-16 F1 · derivative.exercise_price: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2 · derivative.exercise_date: The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting, F3 · derivative.underlying_shares: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer. Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 21:45 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | GrantShare Option (right to buy) · Derivative | 51,804 | $0.00 Strike: $7.37 | $0.00 |
DisclosureSEC source: 0001415889-25-018214 · form4-06252025_050603.xml · derivative · entry 1 TETLOW SHARON · CIK 0001328565 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,804 Underlying: Ordinary Shares · 51,804 shares Expires 2035-06-22 F1 · derivative.exercise_price: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2 · derivative.exercise_date: The shares vest in equal monthly installments over the 12 months following June 23, 2025, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2026 annual shareholder meeting, F3 · derivative.underlying_shares: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer. Read SEC document |
| June 25, 2024 Filed Jun 27, 2024 20:15 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | GrantShare Option (right to buy) · Derivative | 37,500 | $0.00 Strike: $13.32 | $0.00 |
DisclosureSEC source: 0001415889-24-018325 · form4-06272024_040603.xml · derivative · entry 1 TETLOW SHARON · CIK 0001328565 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Ordinary Shares · 37,500 shares Expires 2034-06-24 F1 · derivative.exercise_price: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2 · derivative.exercise_date: The shares vest in equal monthly installments over the 12 months following June 25, 2024. F3 · derivative.underlying_shares: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:38 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | Disposition to issuerStock Option (right to buy) · Derivative | 21,250 | Not disclosed Strike: $14.98 | Not disclosed |
DisclosureSEC source: 0001209191-23-045194 · doc4.xml · derivative · entry 5 TETLOW SHARON · CIK 0001328565 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,250 shares Expires 2032-06-06 F4 · price: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F7 · derivative.exercise_date: The Option is fully vested and exercisable. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:38 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | Disposition to issuerStock Option (right to buy) · Derivative | 13,800 | Not disclosed Strike: $17.00 | Not disclosed |
DisclosureSEC source: 0001209191-23-045194 · doc4.xml · derivative · entry 4 TETLOW SHARON · CIK 0001328565 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,800 shares Expires 2031-09-14 F4 · price: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F6 · derivative.exercise_date: The Option vests as to 1/48th of the total shares monthly, beginning August 20, 2021, subject to the Reporting Holder's continued service to the Registrant. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:38 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | Disposition to issuerStock Option (right to buy) · Derivative | 8,261 | Not disclosed Strike: $17.00 | Not disclosed |
DisclosureSEC source: 0001209191-23-045194 · doc4.xml · derivative · entry 3 TETLOW SHARON · CIK 0001328565 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,261 shares Expires 2031-09-14 F4 · price: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F5 · derivative.exercise_date: The Option vests as to 1/36th of the total shares monthly, beginning January 1, 2021, subject to the Reporting Holder's continued service to the Registrant. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:38 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | Disposition to issuerStock Option (right to buy) · Derivative | 12,096 | Not disclosed Strike: $17.00 | Not disclosed |
DisclosureSEC source: 0001209191-23-045194 · doc4.xml · derivative · entry 2 TETLOW SHARON · CIK 0001328565 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,096 shares Expires 2031-09-14 F4 · price: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3 · derivative.exercise_date: The Company's Stock Option (the "Option") vests as to 1/36th of the total shares monthly, beginning November 8, 2020, subject to the Reporting Holder's continued service to the Registrant. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:38 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | Disposition to issuerCommon Stock | 49,841 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-045194 · doc4.xml · nonDerivative · entry 1 TETLOW SHARON · CIK 0001328565 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On June 18, 2023, DICE Therapeutics, Inc., a Delaware corporation (the "Issuer" or the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Durning Acquisition Corporation, a Delaware corporation and a direct or indirect wholly owned subsidiary of the Parent (the "Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2 · price: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 9, 2023, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased for $48.00 per share (the "Offer Price"), without interest, less any applicable withholding taxes or (y) automatically converted into the right to receive an amount in cash without interest, equal to the Offer Price, less any applicable withholding taxes. Immediately prior to the Closing, any repurchase rights of the Company or other similar restrictions on the Common Stock fully lapsed and all Common Stock became fully vested. Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 21:06 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | GrantStock Option (right to buy Common Stock) · Derivative | 21,250 | $0.00 Strike: $14.98 | $0.00 |
DisclosureSEC source: 0001209191-22-035089 · doc4.xml · derivative · entry 1 TETLOW SHARON · CIK 0001328565 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,250 Underlying: Common Stock · 21,250 shares Expires 2032-06-06 F1 · derivative.exercise_date: The option vests on the earlier to occur of: (i) the one-year anniversary of the grant date and (ii) the subsequent annual meeting of the Registrant's stockholders, in each case, subject to the Reporting Holder's continued service to the Registrant. Read SEC document |
| September 14, 2021 Filed Sep 17, 2021 01:28 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | GrantStock Option (right to buy) · Derivative | 5,600 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-056525 · doc4.xml · derivative · entry 5 TETLOW SHARON · CIK 0001328565 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,600 Underlying: Common Stock · 5,600 shares Expires 2031-09-14 F5 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, beginning August 20, 2021, subject to the Reporting Holder's continued service to the Registrant. Read SEC document |
| September 14, 2021 Filed Sep 17, 2021 01:28 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | GrantStock Option (right to buy) · Derivative | 8,200 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-056525 · doc4.xml · derivative · entry 4 TETLOW SHARON · CIK 0001328565 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,200 Underlying: Common Stock · 8,200 shares Expires 2031-09-14 F5 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, beginning August 20, 2021, subject to the Reporting Holder's continued service to the Registrant. Read SEC document |
| September 14, 2021 Filed Sep 17, 2021 01:28 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | GrantStock Option (right to buy) · Derivative | 8,261 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-056525 · doc4.xml · derivative · entry 3 TETLOW SHARON · CIK 0001328565 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,261 Underlying: Common Stock · 8,261 shares Expires 2031-09-14 F4 · derivative.exercise_date: The option vests as to 1/36th of the total shares monthly, beginning January 1, 2021, subject to the Reporting Holder's continued service to the Registrant. Read SEC document |
| September 14, 2021 Filed Sep 17, 2021 01:28 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | GrantStock Option (right to buy) · Derivative | 12,096 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-056525 · doc4.xml · derivative · entry 2 TETLOW SHARON · CIK 0001328565 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,096 Underlying: Common Stock · 12,096 shares Expires 2031-09-14 F3 · derivative.exercise_date: The option vests as to 1/36th of the total shares monthly, beginning November 8, 2020, subject to the Reporting Holder's continued service to the Registrant. Read SEC document |
| June 09, 2021 Filed Jul 2, 2021 13:55 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001209191-21-044692 · doc4.xml · derivative · entry 1 TETLOW SHARON · CIK 0001328565 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2031-06-09 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest and become exercisable on June 9, 2022, the one-year anniversary of the grant date. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:46 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 1,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-040405 · doc4.xml · nonDerivative · entry 1 TETLOW SHARON · CIK 0001328565 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,635 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 20:48 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.18 | $0.00 |
DisclosureSEC source: 0001209191-20-036316 · doc4.xml · derivative · entry 1 TETLOW SHARON · CIK 0001328565 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2030-06-11 F1 · derivative.exercise_date: The option shall vest monthly over a period of 12 months commencing June 11, 2020. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:43 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 1,932 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-023199 · doc4.xml · nonDerivative · entry 1 TETLOW SHARON · CIK 0001328565 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,932 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 21:07 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.29 | $0.00 |
DisclosureSEC source: 0001209191-20-003942 · doc4.xml · derivative · entry 1 TETLOW SHARON · CIK 0001328565 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-01-15 F1 · derivative.exercise_date: The option shall vest monthly over a period of 36 months commencing January 15, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.